BCL-2 Antagonists: A Proof of Concept for CLL Therapy

Investigational New Drugs - Netherlands
doi 10.1007/s10637-013-0002-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

B Cell CLL/lymphoma 2 (Bcl-2); Inositol-1,4,5-Triphosphate Receptors (IP3R)

Science-Business eXchange
2008English

Crystal Structure of ABT-737 Complexed With BCL-xL: Implications for Selectivity of Antagonists of the BCL-2 Family

Cell Death and Differentiation
Cell BiologyMolecular Biology
2007English

Targeting the BCL-2 Family for Cancer Therapy

Expert Opinion on Therapeutic Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2012English

Computer-Assisted Therapy for Medication-Resistant Auditory Hallucinations: Proof-Of-Concept Study

British Journal of Psychiatry
MedicinePsychiatryMental Health
2013English

BH4 Domain of BCL-2 as a Novel Target for Cancer Therapy

Drug Discovery Today
Drug DiscoveryPharmacology
2016English

Stroke Centers: Proof of Concept and the Concept of Proof

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2010English

Effects of Schema Group Therapy in Older Outpatients: A Proof of Concept Study

International Psychogeriatrics
PsychiatryClinical PsychologyGerontologyGeriatricsMental Health
2014English

Structure-Based Discovery of a New Class of BCL-xL Antagonists

Bioorganic Chemistry
Organic ChemistryBiochemistryDrug DiscoveryMolecular Biology
2007English

Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study

Stem Cells International
Cell BiologyMolecular Biology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy